Related Experiment Video
Updated: Mar 31, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.7K
Sulthiame add-on therapy for epilepsy
Philip Milburn-McNulty1, Graham Powell, Graeme J Sills
1The Walton Centre for Neurology & Neurosurgery NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, UK, L9 7LJ.
The Cochrane Database of Systematic Reviews
|October 29, 2015
Summary
Sulthiame may help stop seizures in West syndrome when added to pyridoxine. However, the evidence is limited due to a small, biased study, and more research is needed for other epilepsies.
Area of Science:
- Neurology
- Clinical Pharmacology
- Evidence Synthesis
Background:
- Epilepsy affects many, with 30% unresponsive to standard treatments.
- Sulthiame is an antiepileptic drug used in Europe and Israel.
- This review summarizes evidence for sulthiame as add-on therapy.
Purpose of the Study:
- To evaluate sulthiame's efficacy as add-on therapy.
- To compare sulthiame's side-effect profile against placebo or other drugs.
Main Methods:
- Searched Cochrane Epilepsy Group, CENTRAL, MEDLINE, ClinicalTrials.gov, WHO ICTRP.
- Included randomized controlled add-on trials of sulthiame for any epilepsy type.
- Assessed seizure frequency reduction, cessation, withdrawal time, and adverse effects.
Main Results:
- One trial (37 participants) with new-onset West syndrome was included.
- Sulthiame as add-on to pyridoxine showed a risk ratio of 0.71 for seizure cessation.
- Insufficient data prevented analysis of withdrawal, adverse effects, or quality of life.
Conclusions:
- Sulthiame may aid seizure cessation in West syndrome when combined with pyridoxine.
- The single study's small size and bias limit the evidence's impact.
- Further large, multi-center trials are essential for sulthiame's use in epilepsy.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
01:30Electroconvulsive Therapy
2.0K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.0K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
956
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
956